Teams of researchers are developing sesame seed-size neuro-implants that detect brain activity that signals depression and then deliver targeted electrical zaps to elevate your mood. It's very early days in the science and technology but recent studies suggest that we're on the path. Links to scientific papers below. Fortunately, the goal is to develop tools and a methodology more precise than the horrifically blunt "shock therapy" of last century. From Science News:

DARPA, a Department of Defense research agency, is funding (Massachusetts General Hospital's research on new brain stimulation methods) plus work at UCLA on targeted brain stimulation. Now in its fifth and final year, the (DARPA) project, called SUBNETS, aims to help veterans with major depression, post-traumatic stress, anxiety and other psychiatric problems. “It is extremely frustrating for patients to not know why they feel the way they do and to not be able to correct it,” Justin Sanchez, the director of DARPA’s Biological Technologies Office, said in a Nov. 30 statement. “We owe them and their families better options.”

These next-generation systems, primarily being developed at UCSF and Massachusetts General Hospital, might ultimately deliver. After detecting altered brain activity that signals a looming problem, these devices, called closed-loop stimulators, would intervene electrically with what their inventors hope is surgical precision.

In contrast to the UCSF group, Widge, who is at the University of Minnesota in Minneapolis, and his collaborators don’t focus explicitly on mood. The researchers want to avoid categorical diagnoses such as depression, which they argue can be imprecise.

I've played enough of Rockstar Games' Red Dead Redemption 2. Read the rest

I’ve always felt the urge to leave. Any place. No matter how beautiful. I want to go. When I was 18 and finished with high school, I attended my graduation ceremony, for the sake of my family, but I skipped my prom – Canada’s east coast was calling. I’d never been there before. I didn’t know what I’d find. But I was going. I made a life for myself out there, with university, work and music. I traveled up and down the coast. Cape Breton feels like a second home to me. I love the people of Maine. New Brunswick and Prince Edward Island have a place in my heart.

But eventually, I left the east. Rage, the self-entitlement that sometimes comes from surviving a shitty childhood and a need for control left me very much out of control. I destroyed a fine long-term relationship looking for who I was. I burned bridges. I did terrible things to myself and others. It was time to move on. My travels took me back home to Ontario. My father was dying. I loved and hated him for who he was and what he had done to our family. Coming home was a terror.

Uneasily settled back into my hometown, I fought to push the dogs of my recent past down into the cellar of my soul where their bark did not seem so loud. I’d gone to university for journalism, but felt too shattered by life to write. I took on a job I despised and worked it for years. Read the rest

Child psychologists have observed an increasing trend in which teens cyberbully themselves, creating anonymous accounts in which they post vicious insults and slurs that seem to be directed to them by strangers. Read the rest

Wil Wheaton has publicly discussed his anxiety and depression before; I know several people whose lives were improved by reading what he had to say. Read the rest

Being medicated is the best and the absolute worst.

I take a cocktail of anti-anxiety and anti-depressive drugs on a daily basis to help me deal with the symptoms that come with my PTSD. Most of the time, I'm grateful for them: They've helped to numb me, just enough so that I can use the techniques I've learned in therapy to help ground myself during a flashback or panic attack. Now that I'm medicated – I refused treatment for years – I'm able to maintain a healthy relationship.

The rage and detachment I've experienced these past 20 years have been tamped down far enough that I can empathize, fully, with my wife, friends and colleagues. It's hard work, sometimes! But I feel healthier than I have in years. A lot of the time, I'm even able to sleep through the night. The paranoia I deal with and the thoughts that refuse to stop tumbling around in my head give way to slumber, most evenings. It's still a frequent thing for me to wake up, sweat-drenched and alert in the dead of night, but it feels manageable. Before, it was just exhausting and sad.

But then, on occasion, a doctor decides that maybe I should be on something new; something different. This happened two days ago. I'm not digging it.

I was warned: when starting on these new pills (no, I'm not going to tell you what they are) I'd experience more anxiety for the next few weeks as the old drugs leave my system and my new pharmaceutical hotness takes hold. Read the rest

Since the earliest days of Facebook, social scientists have sent up warnings saying that the ability to maintain separate "contexts" (where you reveal different aspects of yourself to different people) was key to creating and maintaining meaningful relationships, but Mark Zuckerberg ignored this advice, insisting that everyone be identified only by their real names and present a single identity to everyone in their lives, because anything else was "two-faced." Read the rest

The prohibition on psychedelics was memorably described as "the worst case of scientific censorship since the Catholic Church banned the works of Copernicus and Galileo" by former UK Drugs Czar David Nutt, and despite the ban, there has been a consistent, determined, very promising (sometimes surprising) drumbeat of scientific papers about the use of psilocybin ("magic mushrooms") and other psychedelics in treating a range of chronic illnesses, including mental illnesses. Read the rest

A newly-published overview of self-reported ayahuasca experiences indicates that the hallucinogen can help alleviate eating disorders and reduce alcohol consumption. Now, more scientists are pushing to make it easier to study the drug legally. Read the rest

In High intelligence: A risk factor for psychological and physiological overexcitabilities, a group of academic and industry neuroscientists survey a self-selected group of 3,715 MENSA members about their mental health history and find a correlation between high IQ and clinical anxiety and depression disorders, an effect they attribute to "overexitabilities" -- "the same heightened awareness that inspires an intellectually gifted artist to create can also potentially drive that same individual to withdraw into a deep depression." Read the rest

John Brownlee lost his father to a heart attack. But it was Bruce Brownlee's depression that slowly killed him: My Father The Werewolf.

"I think about my father’s generosity a lot. My father was generous, but he was also depressed, and the nature of depression is to be selfish: to starve those who love you of the best of you, in the relentless feeding of that which can never be nourished. In that, he—the most depressed person I ever met—was also the most selfish. For my entire life, he would give me anything I asked for, as long as it was a movie or a book. But when my mother and I begged him half a dozen times to go see a doctor if he loved us, he wouldn’t lift a finger. How do generosity and selfishness co-exist like that in a person without destroying him?

I don’t know. And, of course, it did eventually destroy him. But that was my father: a lycanthrope of contrasts. Whatever he was, he was also the opposite."

I met Bruce just once and it struck me that every path to him was gated with thorns, and I thought it grew from the reading. But I'm struck more by his son's effort to break through, to finish a story that couldn't be written until the last word was said.

My Father The Werewolf [Pillpack] Read the rest

Ketamine is a short-acting dissociative anesthetic commonly used on animals and sometimes people. Of course it's also beloved by many psychonauts for its unusual dreamlike or "out of body" psychedelic effects. While Ketamine has been shown for years to help treat depression, anxiety, and obsessive-compulsive disorder in adults, researchers at Yale School of Medicine now report that it has great promise as a fast-acting intervention for children in crisis. From Scientific American:

It was less dramatic to watch than I expected, but the kids were definitely high. There was a lot of giggling involved, and they often said that they felt like time was changing and that their bodies felt ‘funny’ and sometimes numb. Nicole, (a suicidal 14-year-old,) admitted, “I’m not gonna lie. I like the feeling of it.”

Perhaps more dramatic than the trips themselves, which happened in a carefully controlled procedure room with a psychiatrist and anesthesiologist ready to intervene if needed, were the interviews that came after. I could see the weight of depression lifted from these patients within hours. Adolescents who were previously ready to end their own lives became bright and hopeful. Psychiatry has never seen a drug intervention so powerful and fast acting. While most anti-depressants take weeks to work and offer modest improvement, ketamine offers dramatic improvement in less than a day...

Dr. Michael Bloch, Yale child psychiatrist and principal investigator of several controlled trials for ketamine for adolescents, points out that the drug is only used for select patients who have severe mental health problems that have not responded to other medications.

A pair of social scientists from UCSD and Yale conducted an NIH study published in the American Journal of Epidemiology on the link between Facebook use and mental health, drawing on data from the Gallup Panel Social Network Study combined with "objective measures of Facebook use" and self-reported data for 5,208 subjects, and concluded that increased Facebook use is causally linked with depression. Read the rest

In the last decade, researchers at Johns Hopkins University and elsewhere have launched new studies investigating whether psychedelic drugs, from shrooms to LSD to DMT, can treat mental disorders ranging from depression and PTSD to anxiety and obsessive-compulsive disorder. Vox reporters German Lopez and Javier Zarracina surveyed the state of medical research on hallucinogens:

In a recent study, British researchers used brain imaging techniques to gauge how the brain looks on LSD versus a placebo. They found big differences between LSD and the placebo, with the images of the brain on LSD showing much more connectivity between different sections of the mind.

This can help explain visual hallucinations, because it means various parts of the brain — not just the visual cortex at the back of the mind — are communicating during an LSD trip.

This, researchers argued, may show not just why psychedelic drugs trigger hallucinogenic experiences but also why they may be able to help people. "In many psychiatric disorders, the brain may be viewed as having become entrenched in pathology, such that core behaviors become automated and rigid," the researchers wrote. "Consistent with their ‘entropic’ effect on cortical activity, psychedelics may work to break down such disorders by dismantling the patterns of activity on which they rest."

"The fascinating, strange medical potential of psychedelic drugs, explained in 50+ studies" (Vox)

Read the rest

Sarah Kurchak, a personal trainer who has experienced clinical depression, offers the most humane advice for using exercise you're likely to find. Read the rest

Nature Magazine reports that researchers from Imperial College London gave psilocybin to 12 people with depression. All the patients showed "a marked improvement in their symptoms."

From Nature:

Researchers from Imperial College London gave 12 people psilocybin, the active component in magic mushrooms. All had been clinically depressed for a significant amount of time — on average 17.8 years. None of the patients had responded to standard medications, such as selective serotonin re-uptake inhibitors (SSRIs), or had electroconvulsive therapy.

One week after receiving an oral dose of psilocybin, all patients experienced a marked improvement in their symptoms. Three months on, five patients were in complete remission.

“That is pretty remarkable in the context of currently available treatments,” says Robin Carhart-Harris, a neuropsychopharmacologist at Imperial College London and first author of the latest study, which is published in The Lancet Psychiatry.

The equivalent remission rate for SSRIs is around 20%.